# Veru Inc.: overview VERU · Nasdaq · CIK 863894 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/veru.md) · [Financials](/companies/veru/financials.md) · [Filings](/companies/veru/filings.md) · [Insiders](/companies/veru/insiders.md) Latest reported revenue: [$0](/filings/0001437749-25-026072.md) for Q3 FY2025, three months to 2025-06-30, from the 10-Q filed Aug 12, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-25-026072). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.7 d](/filings/0001437749-24-037576.md) | not reported | [0.0](/filings/0001437749-25-015330.md) | [0.0](/filings/0001437749-25-026072.md) | not reported | not reported | not reported | not reported | | Gross margin | % | [40.4% d](/filings/0001437749-24-037576.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(140.4%) d](/filings/0001437749-25-038089.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(128.2%) d](/filings/0001437749-25-038089.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(4.4) d](/filings/0001437749-25-038089.md) | [(11.3)](/filings/0001437749-26-003725.md) | [(7.7) d](/filings/0001437749-26-016557.md) | [(5.5) d](/filings/0001437749-26-026664.md) | [(5.5) d](/filings/0001437749-25-038089.md) | [(6.2)](/filings/0001437749-26-003725.md) | [(8.9) d](/filings/0001437749-26-016557.md) | [(5.5) d](/filings/0001437749-26-026664.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [61.3](/filings/0000863894-22-000017.md) | [39.4](/filings/0000863894-24-000006.md) | [16.3](/filings/0001437749-24-037576.md) | [16.9](/filings/0001437749-24-037576.md) | not reported | | Gross margin | % | [78.2%](/filings/0000863894-22-000017.md) | [77.7%](/filings/0000863894-24-000006.md) | [46.4%](/filings/0001437749-24-037576.md) | [34.7%](/filings/0001437749-24-037576.md) | not reported | | Operating margin | % | [21.2%](/filings/0000863894-22-000017.md) | [(212.1%)](/filings/0000863894-24-000006.md) | [(575.5%)](/filings/0001437749-24-037576.md) | [(214.2%)](/filings/0001437749-25-038089.md) | not reported | | Net margin | % | [12.1%](/filings/0000863894-22-000017.md) | [(213.5%)](/filings/0000863894-24-000006.md) | [(571.6%)](/filings/0001437749-24-037576.md) | [(223.9%)](/filings/0001437749-25-038089.md) | not reported | | Diluted EPS | $ per share | [0.09](/filings/0000863894-22-000017.md) | [(1.05)](/filings/0000863894-24-000006.md) | [(1.10)](/filings/0000863894-24-000006.md) | not reported | not reported | | Free cash flow | $m | [(15.9)](/filings/0000863894-22-000017.md) | [(48.2)](/filings/0000863894-24-000006.md) | [(88.7)](/filings/0001437749-24-037576.md) | [(21.8)](/filings/0001437749-25-038089.md) | [(30.0)](/filings/0001437749-25-038089.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/veru/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.2m | 698,439 | | Added +159,057 | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $746.7k | 238,556 | | Reduced −761,444 | | [OPPENHEIMER & CO INC](/funds/822581.md) | 2026-06-30 | $659.9k | 210,843 | | Added +14,543 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $523.0k | 167,084 | | Added +52,915 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $514.7k | 164,450 | | Added +95,200 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $485.5k | 155,076 | | Reduced −29,546 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $452.3k | 144,500 | Put | Added +118,900 | | [Summit Financial, LLC](/funds/1765536.md) | 2026-06-30 | $444.0k | 141,865 | | Reduced −9,918 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $400.2k | 127,853 | | Added +105,046 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $295.5k | 94,400 | Call | Added +84,200 | ## Recent filings [All 953 filings](/companies/veru/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-08 | 08:17 ET | [8-K](/filings/0001193125-26-384430.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-384430 | | 2026-08-10 | 08:51 ET | [10-Q](/filings/0001437749-26-026664.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026664 | | 2026-08-10 | 07:00 ET | [8-K](/filings/0001193125-26-341187.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-341187 | | 2026-07-02 | 16:08 ET | [8-K](/filings/0001193125-26-294507.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-294507 | | 2026-06-04 | 08:30 ET | [8-K](/filings/0001437749-26-019478.md) | 8.01 Other events | 0001437749-26-019478 | | 2026-05-13 | 09:09 ET | [10-Q](/filings/0001437749-26-016557.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016557 | | 2026-05-13 | 07:00 ET | [8-K](/filings/0001193125-26-220569.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-220569 | | 2026-03-13 | 16:04 ET | [8-K](/filings/0001437749-26-008216.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-008216 | | 2026-02-11 | 10:32 ET | [10-Q](/filings/0001437749-26-003725.md) | Quarterly report, period 2025-12-31 | 0001437749-26-003725 | | 2026-02-11 | 07:00 ET | [8-K](/filings/0001193125-26-045527.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-045527 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001437749-25-038089.md), filed Dec 17, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 863894 - Tickers: VERU - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: WI - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.